Stockscreener 앱 받기
77.73
2.81%
-2.25
전일 마감가:
$79.98
열려 있는:
$79.69
하루 거래량:
1.50M
Relative Volume:
1.08
시가총액:
$9.15B
수익:
$12.50B
순이익/손실:
$314.00M
주가수익비율:
31.86
EPS:
2.44
순현금흐름:
$421.00M
1주 성능:
+2.52%
1개월 성능:
+0.49%
6개월 성능:
+12.49%
1년 성능:
+6.16%
1일 변동 폭
$77.53
$79.80
1주일 범위
$74.90
$80.10
52주 변동 폭
$60.56
$82.49
헨리 샤인 Stock (HSIC) Company Profile
명칭
Henry Schein Inc
전화
(631) 843-5500
주소
135 DURYEA RD, MELVILLE, NY
HSIC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
77.73 | 9.42B | 12.50B | 314.00M | 421.00M | 2.44 |
|
MCK
Mckesson Corporation
|
821.84 | 103.74B | 387.09B | 4.23B | 6.01B | 32.12 |
|
COR
Cencora Inc
|
350.67 | 68.84B | 321.33B | 1.57B | 3.21B | 7.9518 |
|
CAH
Cardinal Health Inc
|
210.37 | 50.48B | 234.31B | 1.61B | 4.45B | 6.6243 |
|
AHG
Akso Health Group Adr
|
1.52 | 873.34M | 2.22M | -5.63M | -1.68M | -0.24 |
헨리 샤인 Stock (HSIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-08-26 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-02-14 | 개시 | Wells Fargo | Equal Weight |
| 2025-01-06 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-12-04 | 개시 | Mizuho | Neutral |
| 2024-07-22 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-11-10 | 업그레이드 | Stifel | Hold → Buy |
| 2022-08-08 | 업그레이드 | UBS | Sell → Neutral |
| 2022-07-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-06-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-13 | 재개 | Credit Suisse | Outperform |
| 2022-01-31 | 개시 | Morgan Stanley | Underweight |
| 2022-01-07 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-10-01 | 재개 | Credit Suisse | Neutral |
| 2021-02-08 | 재개 | Piper Sandler | Overweight |
| 2021-01-04 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-11-03 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-04-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-04-02 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-09 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2020-01-02 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2019-08-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-05-30 | 개시 | Wolfe Research | Underperform |
| 2019-05-15 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-04-18 | 개시 | Guggenheim | Buy |
| 2019-01-17 | 개시 | UBS | Sell |
| 2019-01-03 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2019-01-02 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2018-11-08 | 재확인 | Barrington Research | Outperform |
| 2018-10-25 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2018-10-19 | 재개 | Goldman | Neutral |
| 2018-10-04 | 재확인 | Robert W. Baird | Outperform |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-04-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-04-04 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
모두보기
헨리 샤인 주식(HSIC)의 최신 뉴스
The Truth About Henry Schein Inc: Why Wall Street Is Watching (But TikTok Barely Cares…Yet) - AD HOC NEWS
Mizuho Adjusts Price Target on Henry Schein to $81 From $74, Maintains Neutral Rating - marketscreener.com
Here's What to Expect From Henry Schein's Next Earnings Report - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX) - The Globe and Mail
Mixed Strategic Drivers Led Upslope Capital Management to Pick Henry Schein (HSIC) - Insider Monkey
Tetratherix executes global distribution & supply agreement with Henry Schein - marketscreener.com
Tetratherix Executes Global Distribution & Supply Agreement With Henry Schein - TradingView — Track All Markets
Newly listed biotech Tetratherix secures global distribution deal with US giant Henry Schein - Business News Australia
Australia's Tetratherix hits four-week high on supply deal with Henry Schein - TradingView — Track All Markets
Henry Schein names new CEO - DrBicuspid.com
Henry Schein (HSIC) Valuation Check After Exclusive CitoCBC Distribution Agreement - Yahoo Finance
Henry Schein inks exclusive U.S. distribution deal for CLIA-waived CBC system - Medical Economics
Henry Schein enters distribution agreement for CytoChip's CLIA-waived hematology analyzer - marketscreener.com
Henry Schein Enters Distribution Agreement For CytoChip’S CLIA-Waived Hematology Analyzer - TradingView — Track All Markets
Henry Schein Agrees to Distribute CytoChip's CitoCBC system - marketscreener.com
Henry Schein (HSIC) Partners with CytoChip for Exclusive Distrib - GuruFocus
Henry Schein to distribute FDA-cleared blood test system nationwide - Investing.com
Henry Schein to distribute FDA-cleared blood test system nationwide By Investing.com - Investing.com South Africa
Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer - joplinglobe.com
3 Reasons to Sell HSIC and 1 Stock to Buy Instead - Yahoo Finance
JPM26: Henry Schein focuses on high-margin, high-growth business as new CEO announced - Yahoo Finance
Henry Schein extends private placement facilities to 2028 - MSN
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term - sharewise.com
Henry Schein Seeks M&A Opportunities - marketscreener.com
Henry Schein Taps Former Thermo Fisher Exec as New CEO - Modern Distribution Management
Will Henry Schein’s (HSIC) New External CEO and Governance Shift Reframe Its Leadership Narrative? - simplywall.st
Henry Schein Names Thermo Fisher Exec Fred Lowery as CEO - Medical Product Outsourcing
Frederick Lowery named new CEO of Henry Schein, effective March 2026 - Investing.com Nigeria
Leadership transition at Henry Schein: Frederick M. Lowery to take over as CEO - Dental Tribune US
Henry Schein names Frederick M. Lowery as new CEO - newsday.com
Henry Schein Appoints Frederick M Lowery as New CEO - Orthodontic Products
Henry Schein, Inc. Announces Management Changes - marketscreener.com
Henry Schein, Inc. Appoints Frederick M. Lowery as Chief Executive Officer, Effective March 2, 2026 - marketscreener.com
Henry Schein names Frederick Lowery as new CEO - Long Island Business News
Henry Schein appoints industry veteran Frederick M. Lowery as new CEO - Oral Health Group
Henry Schein, Inc. (HSIC) Announces New CEO Appointment - GuruFocus
Henry Schein picks new CEO with significant healthcare distribution experience - MassDevice
Henry Schein (HSIC) Appoints Frederick Lowery as New CEO - GuruFocus
Henry Schein Names Frederick Lowery Chief Executive - marketscreener.com
Henry Schein Names Frederick M. Lowery as Chief Executive Officer - StreetInsider
Henry Schein appoints new CEO amid governance changes - TipRanks
Henry Schein Appoints Frederick M. Lowery as Chief Executive Officer - citybiz
Henry Schein Stock Tests Investor Patience As Healthcare Distribution Re?rates - AD HOC NEWS
Can Henry Schein Inc. stock maintain growth trajectoryQuarterly Portfolio Review & Fast Gain Stock Trading Tips - Улправда
Henry Schein (HSIC) Q1 Earnings Beat Estimates - sharewise.com
SG Americas Securities LLC Decreases Stock Position in Henry Schein, Inc. $HSIC - MarketBeat
Is Henry Schein (HSIC) Pricing Look Attractive After Recent 4.5% Weekly Gain - simplywall.st
Will Henry Schein Inc. stock split attract more investorsWeekly Gains Summary & Real-Time Chart Pattern Alerts - Улправда
Is Henry Schein Inc. stock a safe investment in uncertain markets2025 Trade Ideas & Daily Chart Pattern Signal Reports - ulpravda.ru
Is Henry Schein Inc. stock a bargain at current levels2025 Market Sentiment & Risk Managed Investment Signals - ulpravda.ru
Henry Schein (HSIC) Valuation Check As CEO Retirement Delay Puts Succession Planning In Focus - simplywall.st
헨리 샤인 (HSIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.41%
0.00%
자본화:
|
볼륨(24시간):